Lifeward (NASDAQ:LFWD) Trading Down 2.7% – Should You Sell?

Shares of Lifeward Ltd. (NASDAQ:LFWD) traded down 2.7% on Wednesday . The company traded as low as $1.02 and last traded at $1.07. 121,585 shares traded hands during trading, a decline of 83% from the average session volume of 695,758 shares. The stock had previously closed at $1.10.

Analyst Ratings Changes

A number of research analysts have commented on LFWD shares. Lake Street Capital reduced their price objective on shares of Lifeward from $4.50 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th. HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of Lifeward in a research note on Tuesday, March 11th.

Lifeward Stock Down 2.7%

The firm’s 50 day simple moving average is $1.31 and its two-hundred day simple moving average is $1.57. The stock has a market cap of $11.78 million, a P/E ratio of -0.35 and a beta of 0.16.

Lifeward (NASDAQ:LFWD) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.13). Lifeward had a negative return on equity of 101.96% and a negative net margin of 108.21%. The business had revenue of $5.03 million for the quarter, compared to analyst estimates of $5.84 million. As a group, equities analysts predict that Lifeward Ltd. will post -1.78 EPS for the current year.

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.